Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
On the whole, lean individuals had lower prevalence for these conditions than people with overweight or obesity.
Twelve states have an adult obesity prevalence of 35% or more.
The prevalence of abnormal liver tests in people hospitalized with COVID-19 is higher than previously found.
Age, underlying medical conditions, race/ethnicity and economic status all play a role in determining the risk for severe illness.
Lowering body mass index from obese to overweight cuts individuals’ risk of death by more than half later in life.
“Will we have a COVID vaccine next year tailored to the obese? No way."
Targeting a protein called cyclin D1 may be beneficial in cancer treatment in the setting of obesity and Type 2 diabetes.
The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.
Obesity increased the risk of liver disease to a smaller extent, according to a meta-analysis study.
This connection may be attributable to lower iron levels.
Nearly a quarter of lean HIV-positive people in a recent study had NAFLD, and 16% of them developed fibrosis.
This finding comes from data on COVID-19 cases diagnosed in people with chronic liver disease and reported to international registries.
This benefit was independent of weight control among the animals.
And yet there are no guidelines for screening for the disease in non-obese adolescents.
People with fatty liver disease may have more trouble losing weight
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.